公开(公告)号：US08299062B2

公开(公告)日：2012-10-30

申请号：US10943502

申请日：2004-09-17

申请人： Franklin Volvovitz

发明人： Franklin Volvovitz

IPC分类号： A61K31/27 ,  A61K31/435 ,  A61K31/47 ,  A61K31/55 ,  A61K31/4353 ,  A61K31/4748 ,  A61K31/445 ,  A61K31/5513 ,  A61K31/551 ,  A61K31/216

CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

公开(公告)号：US06485729B1

公开(公告)日：2002-11-26

申请号：US09372734

申请日：1999-08-11

申请人： Gail Eugene Smith ,  James T. Matthews ,  Edwin D. Kilbourne ,  Bert E. Johansson ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett ,  Franklin Volvovitz

发明人： Gail Eugene Smith ,  James T. Matthews ,  Edwin D. Kilbourne ,  Bert E. Johansson ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett ,  Franklin Volvovitz

IPC分类号： A61K39145

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K48/00 ,  A61K2039/5252 ,  A61K2039/55516 ,  A61K2039/70 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/035 ,  C07K2319/036 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2710/14143 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16234

摘要： An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be administered with an adjuvant. The vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection. Oral, nasal or other mucosal or per needle administration, including intracutaneous, intradermal, intramuscular, intravascular, and intravenous, are included.

摘要翻译： 一种抗流感疫苗组合物，其中改进之处在于疫苗包含作为添加剂的神经氨酸酶（NA）。 基础抗流感疫苗可以是任何市售的抗流感疫苗。 该组合物可以包括并且与佐剂一起施用。 疫苗组合物在宿主，动物或人体中提供针对流感感染的保护，包括病毒复制和全身感染。 包括皮下，皮内，肌内，血管内和静脉内的口服，鼻或其他粘膜或每针给药。

公开(公告)号：US5762939A

公开(公告)日：1998-06-09

申请号：US120607

申请日：1993-09-13

申请人： Gale Eugene Smith ,  Franklin Volvovitz ,  Bethanie Eident Wilkinson ,  Craig Stanway Hackett

发明人： Gale Eugene Smith ,  Franklin Volvovitz ,  Bethanie Eident Wilkinson ,  Craig Stanway Hackett

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/145 ,  A61P31/16 ,  A61P37/04 ,  C07K20060101 ,  C07K14/085 ,  C07K14/11 ,  C07K14/155 ,  C07K14/82 ,  C07K19/00 ,  C12N20060101 ,  C12N5/10 ,  C12N9/24 ,  C12N15/44 ,  C12N15/62 ,  C12N15/86 ,  C12N15/866 ,  C12P21/02

CPC分类号： A61K39/145 ,  A61K39/12 ,  C07K14/005 ,  C12N15/625 ,  C12N15/86 ,  A61K2039/55505 ,  A61K2039/70 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/035 ,  C07K2319/036 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2710/14143 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y10S424/816

摘要： A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a trivalent influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. The cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed which can be adapted for the purification of rHA proteins from A sub-types and B type influenza viruses. The procedure produces substantially pure rHA which is a biologically active hemagglutinin, non-denatured, and suitable as a component in human or other animal influenza vaccines.

摘要翻译： 提供了使用DNA技术制备重组流感疫苗的方法。 所得疫苗是基于从具有流行潜力的流感病毒克隆的重组血凝素抗原的混合物的三价流感疫苗。 重组血凝素抗原是全长，未切割（HA0），由培养的昆虫细胞中的杆状病毒表达载体产生的糖蛋白，并在非变性条件下纯化。 从流感A和B病毒克隆流感血凝素基因的过程使用特别设计的寡核苷酸探针和PCR。 然后通过缺失天然疏水信号肽序列修饰克隆的HA基因，并用新的杆状病毒信号肽代替它们。 还公开了用于在昆虫细胞中产生的重组HA蛋白的有效提取和纯化的一般方法，其可适用于从A亚型和B型流感病毒纯化rHA蛋白。 该程序产生基本上纯的rHA，其是生物活性血凝素，非变性的，并且适合作为人或其他动物流感疫苗中的组分。

公开(公告)号：US20120264741A1

公开(公告)日：2012-10-18

申请号：US13530965

申请日：2012-06-22

申请人： Franklin Volvovitz

发明人： Franklin Volvovitz

IPC分类号： A61K31/55 ,  A61P39/02

CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

公开(公告)号：US20090048234A1

公开(公告)日：2009-02-19

申请号：US10943502

申请日：2004-09-17

申请人： Franklin Volvovitz

发明人： Franklin Volvovitz

IPC分类号： A61K31/55 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4748 ,  A61K31/5513 ,  A61K31/216 ,  A61K31/551 ,  A61K31/445 ,  A61K31/4353 ,  A61K31/47

CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

公开(公告)号：US06951649B2

公开(公告)日：2005-10-04

申请号：US10264813

申请日：2002-10-04

申请人： Gail Eugene Smith ,  James T. Matthews ,  Edwin D Kilbourne ,  Bert E. Johansson ,  Bethanie E. Wilkinson ,  Andrie I. Voznesensky ,  Craig S. Hackett ,  Franklin Volvovitz

发明人： Gail Eugene Smith ,  James T. Matthews ,  Edwin D Kilbourne ,  Bert E. Johansson ,  Bethanie E. Wilkinson ,  Andrie I. Voznesensky ,  Craig S. Hackett ,  Franklin Volvovitz

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K48/00 ,  C07K14/11 ,  C12N15/33 ,  A61K39/295

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K48/00 ,  A61K2039/5252 ,  A61K2039/55516 ,  A61K2039/70 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/035 ,  C07K2319/036 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2710/14143 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16234

摘要： The present invention relates to a method for formulating a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement of the vaccine composition is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The improved composition can include and be administered with an adjuvant. The improved vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection.

摘要翻译： 本发明涉及一种配制包含抗流感疫苗的疫苗组合物的方法，其中疫苗组合物的改进是疫苗包含作为添加剂的神经氨酸酶（NA）。 基础抗流感疫苗可以是任何市售的抗流感疫苗。 改进的组合物可以包含佐剂和与佐剂一起施用。 改进的疫苗组合物在宿主，动物或人体中提供针对流感感染的保护，包括病毒复制和全身感染。

公开(公告)号：US06245532B1

公开(公告)日：2001-06-12

申请号：US09169027

申请日：1998-10-09

申请人： Gale E. Smith ,  Franklin Volvovitz ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett

发明人： Gale E. Smith ,  Franklin Volvovitz ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett

IPC分类号： C12N1562

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/035 ,  C07K2319/036 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2710/14143 ,  C12N2760/16122 ,  C12N2760/16222 ,  Y10S977/917

摘要： A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed for the purification of rHA proteins from A sub-types and B type influenza viruses. The procedure produces substantially pure rHA which is a biologically active hemagglutinin, non-denatured, and suitable as a component in human or other animal influenza vaccines.

摘要翻译： 提供了使用DNA技术制备重组流感疫苗的方法。 所得疫苗是基于从具有流行潜力的流感病毒克隆的重组血凝素抗原的混合物的多价，优选三价流感疫苗。 重组血凝素抗原是全长，未切割（HA0），由培养的昆虫细胞中的杆状病毒表达载体产生的糖蛋白，并在非变性条件下纯化。 重组疫苗可以从流感的主要来源开发，例如来自感染个体的鼻分泌物，而不是从鸡卵中适应和培养的病毒。 从流感A和B病毒克隆流感血凝素基因的过程使用特别设计的寡核苷酸探针和PCR。 在优选的实施方案中，然后通过缺失天然疏水信号肽序列修饰克隆的HA基因并用新的杆状病毒信号肽代替它们。 还公开了在昆虫细胞中产生的重组HA蛋白的有效提取和纯化的一般方法用于从A亚型和B型流感病毒纯化rHA蛋白。 该程序产生基本上纯的rHA，其是生物活性血凝素，非变性的，并且适合作为人或其他动物流感疫苗中的组分。

公开(公告)号：US5858368A

公开(公告)日：1999-01-12

申请号：US453848

申请日：1995-05-30

申请人： Gale E. Smith ,  Franklin Volvovitz ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett

发明人： Gale E. Smith ,  Franklin Volvovitz ,  Bethanie E. Wilkinson ,  Andrei I. Voznesensky ,  Craig S. Hackett

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/145 ,  A61P31/16 ,  A61P37/04 ,  C07K20060101 ,  C07K14/085 ,  C07K14/11 ,  C07K14/155 ,  C07K14/82 ,  C07K19/00 ,  C12N20060101 ,  C12N5/10 ,  C12N9/24 ,  C12N15/44 ,  C12N15/62 ,  C12N15/86 ,  C12N15/866 ,  C12P21/02 ,  A61K39/295

CPC分类号： A61K39/145 ,  A61K39/12 ,  C07K14/005 ,  C12N15/625 ,  C12N15/86 ,  A61K2039/55505 ,  A61K2039/70 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/035 ,  C07K2319/036 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2710/14143 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y10S424/816

摘要： A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HAO), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide.

摘要翻译： 提供了使用DNA技术制备重组流感疫苗的方法。 所得疫苗是基于从具有流行潜力的流感病毒克隆的重组血凝素抗原的混合物的多价，优选三价流感疫苗。 重组血凝素抗原是全长，未切割（HAO），由培养的昆虫细胞中的杆状病毒表达载体产生的糖蛋白，并在非变性条件下纯化。 重组疫苗可以从流感的主要来源开发，例如来自感染个体的鼻分泌物，而不是从鸡卵中适应和培养的病毒。 从流感A和B病毒克隆流感血凝素基因的过程使用特别设计的寡核苷酸探针和PCR。 在优选的实施方案中，然后通过缺失天然疏水信号肽序列修饰克隆的HA基因并用新的杆状病毒信号肽代替它们。

公开(公告)号：US20130289021A1

公开(公告)日：2013-10-31

申请号：US13853683

申请日：2013-03-29

申请人： Franklin Volvovitz

发明人： Franklin Volvovitz

IPC分类号： A61K31/439 ,  A61K31/5513 ,  A61K31/46 ,  A61K31/216 ,  A61K45/06 ,  A61K31/4453

CPC分类号： A61K31/439 ,  A61K31/216 ,  A61K31/27 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。

公开(公告)号：US20080090808A1

公开(公告)日：2008-04-17

申请号：US11584017

申请日：2006-10-17

申请人： Franklin Volvovitz

发明人： Franklin Volvovitz

IPC分类号： A61K31/55 ,  A61K31/4745 ,  A61K31/4709

CPC分类号： A61K31/4745 ,  A61K31/4709 ,  A61K31/55 ,  A61K45/06 ,  Y02A50/465 ,  A61K2300/00

摘要： The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging. The compositions of the invention preferably comprise in effective amounts (a) at least one acetylcholinesterase inhibitor, (b) at least one compound with anticholinergic properties or both anticholinergic and antiglutamatergic properties, (c) optionally an anticonvulsive compound, and a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供了用于预防，治疗或逆转由于暴露于有机磷酸盐神经剂，有机磷酸酯杀虫剂和中枢神经系统（CNS）的失能药物引起的哺乳动物的神经元功能障碍的组合物和方法; CNS损伤包括创伤性脑损伤，心脏手术神经并发症，围产期窒息和中风，脊髓损伤和周围神经损伤; 以及与运动功能丧失相关的神经元疾病，包括脊髓灰质炎综合征，肌萎缩性侧索硬化，重症肌无力，帕金森病和Rett综合征; 神经变性疾病包括阿尔茨海默病，轻度认知障碍和精神分裂症; 和与衰老相关的认知障碍。 本发明的组合物优选包含有效量的（a）至少一种乙酰胆碱酯酶抑制剂，（b）至少一种具有抗胆碱能特性或抗胆碱能药和抗谷氨酸能特性的化合物，（c）任选的抗惊厥药物和药学上可接受的载体。